TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cartesian Therapeutics ( (RNAC) ) has shared an announcement.
On November 13, 2025, Cartesian Therapeutics announced promising initial data from its Phase 2 trial of Descartes-08 for systemic lupus erythematosus (SLE), showing significant reductions in disease activity and favorable safety profiles. The company plans to expand Descartes-08 into myositis, with a Phase 2 trial set to begin in the first half of 2026, while pausing further development in SLE to focus on myasthenia gravis and myositis.
The most recent analyst rating on (RNAC) stock is a Sell with a $9.50 price target. To see the full list of analyst forecasts on Cartesian Therapeutics stock, see the RNAC Stock Forecast page.
Spark’s Take on RNAC Stock
According to Spark, TipRanks’ AI Analyst, RNAC is a Neutral.
The overall stock score for Cartesian Therapeutics is primarily influenced by its challenging financial performance and bearish technical indicators. The company’s negative profitability and equity issues are significant concerns, compounded by a negative valuation outlook. While the stock shows potential oversold conditions, the overall sentiment remains cautious due to the high-risk nature of the biotechnology industry.
To see Spark’s full report on RNAC stock, click here.
More about Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage biotechnology company specializing in cell therapy for autoimmune diseases. Their lead product, Descartes-08, is a CAR-T cell therapy in Phase 3 development for generalized myasthenia gravis and is planned for a Phase 2 trial in myositis.
Average Trading Volume: 96,249
Technical Sentiment Signal: Sell
Current Market Cap: $197.1M
See more data about RNAC stock on TipRanks’ Stock Analysis page.